-

EVBG Stock News: Robbins LLP Investigates Everbridge, Inc. (EVBG) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Everbridge, Inc. (NASDAQ: EVBG) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws in relation to the Company's ability to integrate recently purchased companies and their product offerings. Everbridge is a global software company that provides enterprise software applications to automate and accelerate organizations’ operational response to “critical events” in order to keep people safe and organizations running.

If you would like more information about our investigation of Everbridge, Inc.'s misconduct, click here.

What is this Case About: According to a complaint filed against Everbridge, Everbridge went on a buying spree and acquired nine companies between August 2019 and November 2021. During this time, defendants misled investors regarding its ability to integrate these new acquisitions and expectations of revenue growth.

The truth about Everbridge's failings was partially revealed on December 9, 2021, when the Company disclosed the resignation of its CEO, without providing a reason for the decision. The Company also provided 2022 revenue growth guidance of between 20%-23%, well below the expected baseline of 30%. On this news, Everbridge's common stock fell over 45%, or $52.37 per share.

Then, on February 24, 2022, Everbridge announced disappointing financial results for the fourth quarter and full year 2021, and even lower guidance for the first quarter and full year 2022. In so doing, one new interim co-CEO revealed the integration challenges resulting from the buying binge and noted that Everbridge will pause engaging in any new M&A activity to focus on product integration, as well as significantly “simplify” and reduce its product offerings. The other interim co-CEO noted that focus on product integration and simplification would alone result in an approximate $17 million of revenue loss and the decline in deal sizes would result in another $15 million reduction in revenues. On this news, Everbridge’s common stock price fell another $15.68 per share, or 33.9%, to close at $30.61 per share on February 25, 2022.

Next Steps: If you acquired shares of Everbridge, Inc. (EVBG) between November 4, 2019 and February 24, 2022, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Everbridge, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:EVBG

Release Summary
Everbridge, Inc. (NASDAQ: EVBG) is alleged to have misled investors about is ability to integrate recently purchased companies.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom